Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 3, 2014, Pages 255-267

  Gibson, John K ^a   Yue, Yimei ^a   Bronson, Jared ^a   Palmer, Cassie ^a   Numann, Randy ^a,b  

^a Ionic Transport Assays Inc   (United States)

^b NONE   (United States)

Author keywords

Action potentials; APD60; APD90; Human induced stem cell derived cardiomyocytes; Patch clamp method; Rate of rise; Resting membrane potential; Ventricular like myocytes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ASTEMIZOLE; DOFETILIDE; FLECAINIDE; ION CHANNEL; NIFEDIPINE; PENTAMIDINE; POTASSIUM CHANNEL HERG; TERFENADINE; VERAPAMIL; FEXOFENADINE; PHENETHYLAMINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE;

ACTION POTENTIAL DURATION; ADULT; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EARLY AFTERDEPOLARIZATION; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IC50; ION CURRENT; MEMBRANE STEADY POTENTIAL; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; SODIUM CURRENT; VOLTAGE CLAMP TECHNIQUE; ACTION POTENTIAL; ANALOGS AND DERIVATIVES; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ELECTRIC CONDUCTIVITY; METABOLISM;

ACTION POTENTIALS; ADULT; ASTEMIZOLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC CONDUCTIVITY; FLECAINIDE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; ION CHANNELS; MYOCYTES, CARDIAC; NIFEDIPINE; PENTAMIDINE; PHENETHYLAMINES; PIPERIDINES; PYRIDINES; SULFONAMIDES; TERFENADINE; VERAPAMIL;

EID: 84928897709     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.09.005     Document Type: Article

References (43)

1. Aiba T., Shimizu W., Inagaki M., Noda T., Miyoshi S., Ding W.G., et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. Journal of the American College of Cardiology 2005, 45(2):300-307.
2. Cavero I., Mestre M., Heuillet E., Roach A.G. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?. Drug Safety 1999, 21(Supp:1):19-31.
3. Champeroux P., Viaud K., Ilah El Amrani A., Sinclair J., Fowler L., Martel E., et al. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. British Journal of Pharmacology 2005, 144(3):376-385.
4. Davis R.P., Casini S., van den Berg C.W., Hoekstra M., Remme C.A., Dambrot C., et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125(25):3079-3091.
5. De Molis J.-L., Funck-Bretano C., Ropers J., Chanfar M., Nichols D., Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996, 94:1589-1592.
6. Ducroq J., Printemps R., Guilbot S., Salvetat C., Le Grand M. Action potential experiments complete hERG assay and QT- interval measurements in cardiac preclinical studies. Journal of Pharmacological and Toxicological Methods 2007, 56(2):159-170.
7. Follmer C.H., Colatsky T.J. Block of delayed rectifier current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990, 82:289-293.
8. Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacology & Therapeutics 2011, 129(2):109-119.
9. Gintant G.A., Limberis J.T., McDermott J.S., Wegner C.D., Cox B.F. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. Journal of Cardiovascular Pharmacology 2001, 37(5):607-618.
10. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicological Sciences: An Official Journal of the Society of Toxicology 2013, 134(2):412-426.
11. Hondeghem L.M., Dujardin K., Hoffmann P., Dumotier B., De Clerck F. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. Journal of Cardiovascular Pharmacology 2011, 57(5):589-597.
12. ICH S7B (November 2005) European Medicines Agency. ICH Steering Committee. S7B the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf.
13. ICH S7B (October 2005) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Steering Committee. S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals http://www.fda.gov/downloads/RegulatoryInformation/Guidelines/ucm129122.pdf.
14. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacological Reviews 2010, 62(4):760-781.
15. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. The Journal of Pharmacology and Experimental Therapeutics 2005, 312(1):316-323.
16. Lidman C., Bronner U., Gustafsson L.L., Rombo L. Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. The Journal of Antimicrobial Chemotherapy 1994, 33(4):803-810.
17. Lu H.R., Vlaminckx E., Hermans A.N., Rohrbacker J., Van Ammel K., Towart R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. British Journal of Pharmacology 2008, 154(7):1427-1438.
18. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. American Journal of Physiology. Heart and Circulatory Physiology 2011, 301(5):H2006-H2017.
19. Markham A., Wagstaff A.J. Fexofenadine. Drugs 1998, 55:269-274.
20. Marrannes R., De Prins E. Computer programs to facilitate the estimation of time-dependent drug effects on ion channels. Computer Methods and Programs in Biomedicine 2004, 74(2):167-181.
21. Monahan B., Ferguson C., Killeavy E., Lloyd B., Troy J., Cantilena L. Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 1996, 264:278-2790.
22. Naccarelli G.V., Wolbrette D.L., Khan M., Bhatta L., Hynes J., Samii S., et al. Old and new Antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. American Journal of Cardiology 2003, 91(6A):15D-26D.
23. Nakamura Y., Matsuo J., Miyamoto N., Ojima A., Ando K., Kanda Y., et al. Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: Multi-site validation study. Journal of Pharmacological Sciences 2014, 124:494-501.
24. Navarrete E.G., Liang P., Lan F., Sanchez-Freire V., Simmons C., Gong T., et al. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128(11 Suppl. 1):S3-S13.
25. Okada Y., Ogawa S., Sadanaga T., Mitamura H. Assessment of reverse use-dependent blocking actions of class III Antiarrhythmic drugs by 24-hour Holter electrocardiography. Journal of the American College of Cardiology 1996, 27(1):89-94.
26. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. British Journal of Pharmacology 2002, 136:727-729.
27. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2010, 61(3):277-286.
28. Pratt C., Brown A., Rampe D., Mason J., Russell T., Reynolds R., et al. Cardiovascular safety of fexofenadine HCl. Clinical and Experimental Allergy 1999, 55:269-274.
29. Pugsley M.K., Towart R., Authier S., Gallacher D.J., Curtis M.J. Innovation in safety pharmacology testing. Journal of Pharmacological and Toxicological Methods 2011, 64(1):1-6.
30. Puppala D., Collis L.P., Sun S.Z., Bonato V., Chen X., Anson B., et al. Comparative gene expression profiling in human-induced pluripotent stem cell-derived cardiomyocytes and human and cynomolgus heart tissue. Toxicological Sciences: An Official Journal of the Society of Toxicology 2013, 131(1):292-301.
31. Qu Y., Gao B., Fang M., Vargas H.M. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay. Journal of Pharmacological and Toxicological Methods 2013, 68(1):74-81.
32. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 56(1):32-45.
33. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Research 1995, 76:110-119.
34. Salerno C.M., Granrud G., Sharkey P., Krejci J., Larson T., Erlien D., et al. Pharmacodynamics and side effects of flecainide acetate. Clinical Pharmacology Therapeutics 1986, 40(1):101-107.
35. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81(2):299-307.
36. Schimpf R., Veltmann C., Papavassiliu T., Rudic B., Göksu T., Kuschyk J., et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm: The Official Journal of the Heart Rhythm 2012, 9(5):776-781.
37. Shah R.R. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. British Journal of Pharmacology 2010, 159(1):58-69.
38. 2+ channels revealed by Timothy syndrome mutation. European Journal of Pharmacology 2012, 685(1-3):15-23.
39. Spector P.S., Curran M.E., Keating M.T., Sanguinetti M.C. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circulation Research 1996, 78(3):499-503.
40. Tabo M., Hara T., Sone S., Shishido N., Kuramoto S., Nakano K., et al. Prediction of drug-induced QT interval prolongation in telemetered common marmosets. The Journal of Toxicological Sciences 2008, 33(3):315-325.
41. Terrenoire C., Wang K., Tung K.W., Chung W.K., Pass R.H., Lu J.T., et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. The Journal of General Physiology 2013, 141(1):61-72.
42. Uesugi M., Ojima A., Taniguchi T., Miyamoto N., Sawada K. Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2013, S1056-8719(13):321-323.
43. Zhang S., Zhou Z., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circulation Research 1999, 84(9):989-998.